Key result
Adiponectin exhibits anti-inflammatory and anti-atherogenic properties that protect against the initiation and progression of atherosclerosis.
Adiponectin serves as a protective adipokine against atherosclerosis by inhibiting monocyte adhesion, reducing phagocytic activity, and promoting nitric oxide generation.
Supports adiponectin research in atherosclerosis; leaves open clinical translation or practice change pending higher-level evidence.
Adiponectin is secreted by white adipose tissue and as known as for its function it is anti-diabetes, anti-atherosclerosis, anti-inflammation and antitumor activities, which have been directly linked to the high molecular weight and are abundantly present in circulating blood. adiponectin had effects on monocyte adhesion to endothelium, myeloid differentiation and macrophage cytokine production and phagocytosis. It can suppress atherogenesis by inhibiting the adherence of monocytes, reducing their phagocytic activity and suppressing the accumulation of modified lipoproteins in the vascular wall. C1q and TNF family play important roles in inflammation, the immune system and atherosclerosis. Adiponectin has protective actions in the initiation and progression of atherosclerosis through anti-inflammatory and anti-atherogenic effects. Adiponectin levels are decreased in obesity, type 2 diabetes and negatively correlated with the CRP levels in patients with CAD. With the prospect of future, adiponectin could become a promising target for future investigations in reducing the morbidity and mortality of atherosclerotic disease.
No takes yet. Share an insight, caveat, or question.
Majid Khandouzi (2013) conducted a review in Atherosclerosis. Adiponectin was evaluated. Adiponectin exhibits anti-inflammatory and anti-atherogenic properties that protect against the initiation and progression of atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: